SCHEMBL3596741

SCHEMBL3596741

Nc1cccc2c1CC(N1CCC(=O)CC1)C(=O)N2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 8/20 0.41
DDB1 Q16531 6/20 0.41
TNF P01375 3/20 0.41
IL1B P01584 3/20 0.41
IKZF3 Q9UKT9 3/20 0.41
IKZF1 Q13422 2/20 0.41
BRD4 O60885 1/20 0.41
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
TBXA2R P21731 1/20 0.37
RAB9A P51151 1/20 0.36
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
APEX1 P27695 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3606102 0.89 ALDH1A1 (0.43) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3605689 0.88 ALDH1A1 (0.43) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3589421 0.86 ALDH1A1 (0.39) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3590903 0.85 ALDH1A1 (0.44) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3587498 0.85 DRD2 (0.43) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3587351 0.85 ALDH1A1 (0.39) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3596738 0.85 ALDH1A1 (0.40) CRBNDDB1IKZF3ALDH1A1KDM4E
SCHEMBL3592826 0.84 ALDH1A1 (0.40) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3594551 0.84 ALDH1A1 (0.37) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3593131 0.81 KDM4E (0.38) CRBNDDB1TNFIL1BIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 CRBN 762/4885DDB1 1855/4885TNF 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.